Tirzepatide
Weekly dual-hormone injection with the largest weight loss of any approved drug.
- Starts working
- Varies
- Half-life
- About 5 days
- In use since
- 2022
- Pregnancy
- Usually avoided
Overview
Tirzepatide acts on two gut-hormone receptors (GIP and GLP-1). Sold as Mounjaro and Zepbound, it lowers blood sugar strongly and produced around 20% average weight loss at the top dose in trials. It's also approved for obstructive sleep apnoea with obesity.
Conditions it's used for
How it works
Copies two gut hormones that control insulin, appetite and fat storage.
Tirzepatide belongs to the Dual GIP/GLP-1 agonists. How Dual GIP/GLP-1 agonists work: combine the effects of two incretin hormones on insulin, appetite and fat metabolism.
Uses
- Type 2 diabetes
- Obesity and overweight with health problems
- Obstructive sleep apnoea with obesity
Available as: weekly pen or vial injection.
Typical dose
- Adults
- Start 2.5 mg weekly, increasing by 2.5 mg every 4 weeks to 5–15 mg.
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Reduced appetite
Serious — get medical help
Uncommon, but need prompt attention
- Pancreatitis
- Gallbladder disease
- Dehydration and kidney injury
- Aspiration under anaesthesia
Warnings
- Can make the oral contraceptive pill less reliable — use a barrier method for 4 weeks after starting and each dose increase
- Same thyroid cancer precautions as GLP-1 drugs
- Avoid unregulated versions
Interactions
- Oral contraceptives — reduced reliability
- Insulin and sulfonylureas — hypos
Pregnancy and breastfeeding
Usually avoided
Stop at least 1 month before trying to conceive.
Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.
Brand names
- United States
- Mounjaro, Zepbound
- United Kingdom
- Mounjaro
- India
- Mounjaro
- Australia
- Mounjaro
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
History
2022
Mounjaro approved in the US for type 2 diabetes.
2023
Zepbound approved for weight management.
2024
Approved for obstructive sleep apnoea with obesity.
2025
Launched in India; SURMOUNT-5 shows about 20% weight loss versus 14% with semaglutide.
Common questions
Is it stronger than semaglutide?
In a head-to-head trial it produced more weight loss on average, though individual responses vary.
Do I need a prescription for Tirzepatide?
Yes — Tirzepatide is prescription-only in most countries.
Can I take Tirzepatide during pregnancy?
Usually avoided. Stop at least 1 month before trying to conceive. Always check with a doctor or midwife.
Related medicines
Sources and official information
- MedlinePlus (US National Library of Medicine)
- DailyMed — official US labels
- NHS medicines A–Z
- WHO ATC/DDD index — A10BX16
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.